BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

South Korea's SK bioscience expands manufacturing agreement for Novavax's COVID-19 vaccine

December 27, 2021 | News

SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market



Novavax, Inc. and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, have announced the expansion of the companies' collaboration and license agreements for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine.

The companies have agreed that SK bioscience will reserve significant additional manufacturing capacity to produce antigen, a key component of NVX-CoV2373, through 2022, with the possibility to extend the arrangement.

The agreement between the companies also builds on a previously announced advance purchase agreement (APA) between SK bioscience and the Korean government to supply 40 million doses of NVX-CoV2373 for the Republic of Korea.

SK bioscience may supply additional quantities of NVX-CoV2373 in the Korean market in 2022. Additionally, SK bioscience has acquired non-exclusive rights to sell doses of Novavax' vaccine to the governments of Thailand and Vietnam.